2024
Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone.
Patidar K, Tu W, Cotter T, Simonetto D, Asgharpour A, Jan M, Tang Q, Yu Y, Li Y, Taiwo M, Thevkar Nagesh P, Dasarathy S, Kamath P, McClain C, Chalasani N, Szabo G, Bataller R, Mitchell M, Mehal W, Nagy L, Shah V, Gawrieh S, Sanyal A. Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone. Hepatology 2024 PMID: 39028887, DOI: 10.1097/hep.0000000000001019.Peer-Reviewed Original ResearchMultivariable competing-risk analysisCompeting-risk analysisTreatment armsKidney injuryRisk factorsWhite blood cell countMulticenter randomized clinical trialAcute kidney injuryKidney injury biomarkersBaseline risk factorsBlood cell countRandomized clinical trialsAKI developmentClinical factorsPrednisoneFollow-upHepatic encephalopathyArterial pressureClinical trialsDay 7Cell countPatientsTrialsBaselineLower survival
2019
Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis
Do A, Kuszewski EJ, Langberg K, Mehal W. Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. Hepatology 2019, 70: 1443-1456. PMID: 30991446, PMCID: PMC6783325, DOI: 10.1002/hep.30658.Peer-Reviewed Original ResearchConceptsTotal body weight lossWeight loss medicationsNonalcoholic steatohepatitisHepatology clinicStaging of NASHPartial histological responseBody weight lossHepatology practiceNASH histologyLiver histologyClinical profileLiver diseaseLiver triglyceridesNew medicationsClinical trialsHistological responseLifestyle changesPatientsMedicationsUncommonly resultsNatural historyClinical interventionsWeight lossSteatohepatitisHepatologists